NCT05539924

Brief Summary

Pregabalin and gabapentin are both GABA analogue and their mechanism of action is not fully understood. Both drugs when given as a pre-emptive analgesia for spinal surgery were found to reduce intra-and postoperative opioid requirements. Preoperative intramuscular injection of morphine could reduce the patients' pain during the percutaneous transformational endoscopic discectomy "PTED" surgery and improve the patients' satisfaction without affecting the surgical outcome. The efficacy of adding pregabalin or gabapentin to preoperative intramuscular morphine is not yet investigated. The current study aims to compare the analgesic effect of both drugs when given preoperatively with intramuscular morphine.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Sep 2022

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 10, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 14, 2022

Completed
1 day until next milestone

Study Start

First participant enrolled

September 15, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

October 27, 2022

Status Verified

October 1, 2022

Enrollment Period

2 months

First QC Date

September 10, 2022

Last Update Submit

October 24, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • time to first rescue analgesia during the first postoperative 24 hours.

    call for analgesia

    24 hours

Secondary Outcomes (1)

  • pain score

    24 hours post operative

Study Arms (3)

Group P

ACTIVE COMPARATOR

The patients in this group will receive 150 mg pregabalin tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.

Drug: Pregabalin 150mg gabapentin 400mg

Group G

ACTIVE COMPARATOR

The patients in this group will receive 400 mg Gababentin4 tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.

Drug: Pregabalin 150mg gabapentin 400mg

Group C

PLACEBO COMPARATOR

The patients in this group will receive vitamin B12 (100µg) as placebo tablets P.O hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.

Drug: Pregabalin 150mg gabapentin 400mg

Interventions

oral administration

Also known as: vitamin B12
Group CGroup GGroup P

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ASA I and ASA II
  • Elective Lumber micro discectomy.
  • BMI ≤ 35
  • Time of operation not exceeding 2hours.

You may not qualify if:

  • Patients' refusal
  • Age \< 20 years or \> 60 years
  • ASA III to ASA IV
  • Contraindications to Opioids e.g., Allergy, Bronchial asthma.
  • Contraindication to Pregabalin or Gabapentin e.g. Allergy
  • Psychological or mental disorders.
  • Disturbance of Conscious level.
  • Uncooperative patients.
  • Patients with impaired renal function or creatinine clearance less than 50ml/min

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

kasr el aini H

Giza, Egypt

Location

MeSH Terms

Interventions

PregabalinGabapentinVitamin B 12

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and ProteinsAminesCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsCorrinoidsTetrapyrrolesPyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingMacrocyclic CompoundsPolycyclic Compounds

Study Officials

  • mohamed s arafa, MD

    kasr el aini H

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2022

First Posted

September 14, 2022

Study Start

September 15, 2022

Primary Completion

November 1, 2022

Study Completion

November 1, 2022

Last Updated

October 27, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations